Welcome to Angion Biomedica! We are a biopharmaceutical company dedicated to the discovery and development of novel therapeutics that enhance quality of life, eradicate disease and save lives by modulating the body's protective, reparative and regenerative systems.

We provide therapeutic solutions for unmet medical needs in acute and chronic tissue, organ injury and fibrosis. Our discovery and development efforts have yielded a rich and diverse product pipeline comprising novel, small molecule modulators of the HGF/c-Met pathway, inhibitors of PARP and modulators of retinoic acid signaling that are in advanced preclinical or clinical development.

• Angion Biomedica's drug BB3 receives both Fast Track and Orphan Drug designations from FDA.
• Angion Biomedica receives clearance from FDA to start clinical trials in patients with renal disease.
• Angion Biomedica completes first-in-class HGF mimetic Phase IIA clinical trial.